vs

Side-by-side financial comparison of Moderna (MRNA) and Toast, Inc. (TOST). Click either name above to swap in a different company.

Toast, Inc. is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.6× Moderna). Toast, Inc. runs the higher net margin — 6.2% vs -19.7%, a 25.9% gap on every dollar of revenue. On growth, Toast, Inc. posted the faster year-over-year revenue change (22.0% vs -45.4%). Toast, Inc. produced more free cash flow last quarter ($178.0M vs $-880.0M). Over the past eight quarters, Toast, Inc.'s revenue compounded faster (23.3% CAGR vs -45.0%).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Toast, Inc. is an American cloud-based restaurant management software company based in Boston, Massachusetts. The company provides an all-in-one point of sale (POS) system built on the Android operating system.

MRNA vs TOST — Head-to-Head

Bigger by revenue
TOST
TOST
1.6× larger
TOST
$1.6B
$1.0B
MRNA
Growing faster (revenue YoY)
TOST
TOST
+67.5% gap
TOST
22.0%
-45.4%
MRNA
Higher net margin
TOST
TOST
25.9% more per $
TOST
6.2%
-19.7%
MRNA
More free cash flow
TOST
TOST
$1.1B more FCF
TOST
$178.0M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
TOST
TOST
Annualised
TOST
23.3%
-45.0%
MRNA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MRNA
MRNA
TOST
TOST
Revenue
$1.0B
$1.6B
Net Profit
$-200.0M
$101.0M
Gross Margin
79.6%
25.9%
Operating Margin
-25.6%
5.2%
Net Margin
-19.7%
6.2%
Revenue YoY
-45.4%
22.0%
Net Profit YoY
-1638.5%
215.6%
EPS (diluted)
$-0.51
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
TOST
TOST
Q4 25
$1.6B
Q3 25
$1.0B
$1.6B
Q2 25
$1.6B
Q1 25
$1.3B
Q4 24
$966.0M
$1.3B
Q3 24
$1.9B
$1.3B
Q2 24
$1.2B
Q1 24
$1.1B
Net Profit
MRNA
MRNA
TOST
TOST
Q4 25
$101.0M
Q3 25
$-200.0M
$105.0M
Q2 25
$80.0M
Q1 25
$56.0M
Q4 24
$-1.1B
$32.0M
Q3 24
$13.0M
$56.0M
Q2 24
$14.0M
Q1 24
$-83.0M
Gross Margin
MRNA
MRNA
TOST
TOST
Q4 25
25.9%
Q3 25
79.6%
26.5%
Q2 25
25.3%
Q1 25
25.9%
Q4 24
23.5%
24.9%
Q3 24
72.4%
24.7%
Q2 24
23.0%
Q1 24
23.2%
Operating Margin
MRNA
MRNA
TOST
TOST
Q4 25
5.2%
Q3 25
-25.6%
5.1%
Q2 25
5.2%
Q1 25
3.2%
Q4 24
-129.0%
2.5%
Q3 24
-3.8%
2.6%
Q2 24
0.4%
Q1 24
-5.2%
Net Margin
MRNA
MRNA
TOST
TOST
Q4 25
6.2%
Q3 25
-19.7%
6.4%
Q2 25
5.2%
Q1 25
4.2%
Q4 24
-115.9%
2.4%
Q3 24
0.7%
4.3%
Q2 24
1.1%
Q1 24
-7.7%
EPS (diluted)
MRNA
MRNA
TOST
TOST
Q4 25
$0.18
Q3 25
$-0.51
$0.16
Q2 25
$0.13
Q1 25
$0.09
Q4 24
$-2.91
$0.09
Q3 24
$0.03
$0.07
Q2 24
$0.02
Q1 24
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
TOST
TOST
Cash + ST InvestmentsLiquidity on hand
$1.1B
$1.4B
Total DebtLower is stronger
Stockholders' EquityBook value
$9.3B
$2.1B
Total Assets
$12.1B
$3.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
TOST
TOST
Q4 25
$1.4B
Q3 25
$1.1B
$1.4B
Q2 25
$1.2B
Q1 25
$1.0B
Q4 24
$1.9B
$903.0M
Q3 24
$1.6B
$761.0M
Q2 24
$691.0M
Q1 24
$578.0M
Stockholders' Equity
MRNA
MRNA
TOST
TOST
Q4 25
$2.1B
Q3 25
$9.3B
$2.0B
Q2 25
$1.8B
Q1 25
$1.7B
Q4 24
$10.9B
$1.5B
Q3 24
$11.9B
$1.4B
Q2 24
$1.3B
Q1 24
$1.2B
Total Assets
MRNA
MRNA
TOST
TOST
Q4 25
$3.1B
Q3 25
$12.1B
$3.0B
Q2 25
$2.8B
Q1 25
$2.6B
Q4 24
$14.1B
$2.4B
Q3 24
$15.8B
$2.2B
Q2 24
$2.2B
Q1 24
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
TOST
TOST
Operating Cash FlowLast quarter
$-847.0M
$194.0M
Free Cash FlowOCF − Capex
$-880.0M
$178.0M
FCF MarginFCF / Revenue
-86.6%
10.9%
Capex IntensityCapex / Revenue
3.2%
1.0%
Cash ConversionOCF / Net Profit
1.92×
TTM Free Cash FlowTrailing 4 quarters
$-1.9B
$608.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
TOST
TOST
Q4 25
$194.0M
Q3 25
$-847.0M
$165.0M
Q2 25
$223.0M
Q1 25
$79.0M
Q4 24
$825.0M
$147.0M
Q3 24
$-1.6B
$109.0M
Q2 24
$124.0M
Q1 24
$-20.0M
Free Cash Flow
MRNA
MRNA
TOST
TOST
Q4 25
$178.0M
Q3 25
$-880.0M
$153.0M
Q2 25
$208.0M
Q1 25
$69.0M
Q4 24
$303.0M
$134.0M
Q3 24
$-1.7B
$97.0M
Q2 24
$108.0M
Q1 24
$-33.0M
FCF Margin
MRNA
MRNA
TOST
TOST
Q4 25
10.9%
Q3 25
-86.6%
9.4%
Q2 25
13.4%
Q1 25
5.2%
Q4 24
31.4%
10.0%
Q3 24
-92.2%
7.4%
Q2 24
8.7%
Q1 24
-3.1%
Capex Intensity
MRNA
MRNA
TOST
TOST
Q4 25
1.0%
Q3 25
3.2%
0.7%
Q2 25
1.0%
Q1 25
0.7%
Q4 24
54.0%
1.0%
Q3 24
8.1%
0.9%
Q2 24
1.3%
Q1 24
1.2%
Cash Conversion
MRNA
MRNA
TOST
TOST
Q4 25
1.92×
Q3 25
1.57×
Q2 25
2.79×
Q1 25
1.41×
Q4 24
4.59×
Q3 24
-120.46×
1.95×
Q2 24
8.86×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

TOST
TOST

Technology Service$1.3B82%
License$256.0M16%
Product And Professional Services$43.0M3%

Related Comparisons